{"id":2296,"date":"2024-11-28T14:26:15","date_gmt":"2024-11-28T14:26:15","guid":{"rendered":"https:\/\/www.sedapds.com\/news\/"},"modified":"2024-11-29T10:07:06","modified_gmt":"2024-11-29T10:07:06","slug":"andy-burnham-opens-sedas-state-of-the-art-gmp-facility","status":"publish","type":"post","link":"https:\/\/www.sedapds.com\/news\/andy-burnham-opens-sedas-state-of-the-art-gmp-facility\/","title":{"rendered":"Andy Burnham Opens Seda\u2019s State-of-the-Art GMP Facility"},"content":{"rendered":"

Andy Burnham, Mayor of Greater Manchester, Inaugurates Seda\u2019s New State-of-the-Art GMP Facility, Projected to Generate 100 Jobs and Boost UK Life Sciences Sector<\/strong><\/p>\n

Cheadle, Greater Manchester, UK, 22nd November<\/em><\/strong> \u2014 In a significant milestone for the North\u2019s life sciences sector, Andy Burnham, Mayor of Greater Manchester, officially opened Seda Group\u2019s new state-of-the-art drug product GMP (Good Manufacturing Practice) facility. The event was marked by a tour of the cutting-edge site, where Andy was accompanied by Labour MP for Waddon, Councillor Rowenna Davis. This new facility promises to enhance Greater Manchester\u2019s reputation as a hub for life sciences innovation and is expected to create up to 100 high-skilled jobs over the next five years, with more than half of its projected revenue coming from international clients.<\/p>\n

\"\"
Mayor of Greater Manchester, Andy Burnham, with Dr. Paul Dickinson (Seda Co-founder and CSO), Dr. Marcel de Matas (Seda Co-founder and CTO), and Dr. Paul Stott (CEO)<\/figcaption><\/figure>\n

The newly established division, Seda Clinical Manufacturing Services (CMS)<\/strong><\/a>, complements Seda’s existing Pharmaceutical Development Services (PDS)<\/strong><\/a> arm, expanding into GMP manufacturing, testing, and supply. The facility enables Seda to supply investigational medicinal products for testing in clinical studies by their global biotech client partners.<\/p>\n

\"\"
Andy Burnham, Mayor of Greater Manchester, with Paul Stott, Seda CEO<\/figcaption><\/figure>\n

“We are thrilled to expand our capabilities with the launch of Seda CMS, enhancing our support for both domestic and international clients,” said Dr. Paul Stott<\/a>, CEO. “This facility not only generates jobs and revenue but also reinforces the North of England\u2019s role as an innovation hotspot.”<\/p>\n

Located adjacent to Seda Pharmaceutical Development Services (PDS), this expansion builds on nearly a decade of success. Founded in 2015, to address a gap in the market for pharmaceutical development integrated with clinical pharmacology, Seda has consistently innovated to meet unmet client needs and growing demand. In 2019, it relocated to state-of-the-art labs and offices on Cheadle Royal Business Park and saw substantial growth despite the recent economic climate. This \u00a38 million investment, partially funded by Santander NW<\/strong>, positions Seda to supply drugs for Phase 1 and 2 clinical trials, with its robust order book for GMP manufacturing pending MHRA approval and licensing.<\/p>\n

\"\"
Andy Burnham (third from right) with members of the Seda Leadership Team (L-R Linette Ruston, Vijay Masaun, Effi Baetzner, Mike Hingley, Shanoo Budhdeo and Darren Gill)<\/figcaption><\/figure>\n

The opening follows Seda\u2019s recognition with the prestigious 2024 King\u2019s Award for Enterprise in International Trade<\/strong>. Drawing ~60% of its revenue from international markets, Seda exemplifies global trade excellence while driving local economic growth.<\/p>\n

Mayor Andy Burnham\u2019s presence underscored Manchester\u2019s commitment to fostering innovation. “This facility serves to support the local and UK Life Sciences infrastucture\u201d he noted during the tour.<\/p>\n

\"Mayor
Andy Burnham and Councillor Rowenna Davis during a tour of Seda’s state-of-the-art GMP facility<\/figcaption><\/figure>\n